Neurocompute Narrative Velocity Map
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

NC
Neurocompute
AI Parkinson’s Intelligence Terminal
NARRATIVE VELOCITY ENGINE

Neurocompute

AI-driven Parkinson’s research intelligence platform exploring emerging signals, forgotten papers, and therapeutic patterns across the biomedical literature universe.

Indexed Papers
1,516
AI Scored
984
Ranked Papers
998
Coverage
1.3%
RESEARCH INTELLIGENCE BOARD

Ranked Parkinson’s Papers

1516 results
LAST INGEST 2026-05-29 06:45 PM
E
[18F]-Flortaucipir PET/MRI Supports a 4R Tauopathy Phenotype in Corticobasal Degeneration.
PMID 41949407 Published: 2026-03-31 Ingested: 2026-04-28 08:58 PM Clinical nuclear medicine
AI 40.0
Base 30.9
Rank 30.8
AI Summary

Case report where 18F‑Flortaucipir PET showed asymmetric basal ganglia uptake in an amyloid‑negative patient with corticobasal syndrome, supporting a 4R tauopathy phenotype and suggesting expanded utility of this tracer beyond its current FDA indication.

Why It Matters

Supports use of tau PET as a diagnostic biomarker in 4R tauopathies associated with atypical parkinsonism, which could improve patient selection and outcome measures for tau‑targeted therapeutic development.

E
AI 20.0
Base 31.0
Rank 30.8
AI Summary

Narrative review of neurology studies (2020–2025) using the German IQVIA Disease Analyzer highlighting outpatient diagnoses, prescribing patterns, and methodological strengths and limitations across disorders including Parkinson’s disease.

Why It Matters

Provides useful real-world epidemiology and treatment-pattern context for Parkinson’s but offers minimal mechanistic, biomarker, or intervention insights needed for direct therapeutic discovery, so it mainly guides study design and complementary data needs.

E
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review.
PMID 41938822 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Biologics : targets & therapy
AI 48.0
Base 32.6
Rank 30.7
AI Summary

This systematic review of seven small trials (123 participants) reports that mesenchymal stem cell therapy in MSA is generally safe and was associated in some studies with dose‑dependent slowing of clinical progression, but findings are heterogeneous across routes, doses, and study designs.

Why It Matters

MSCs act via anti‑inflammatory and trophic mechanisms that are potentially disease‑modifying for synucleinopathies, making this preliminary clinical signal of neuroprotection relevant to Parkinson's therapeutic discovery, though evidence is limited and requires larger, standardized trials to assess…

E
Mobile EEG assessment of inhibitory control during dual-task walking in Parkinson's disease.
PMID 41962423 Published: 2026-04-08 Ingested: 2026-04-28 08:58 PM Parkinsonism & related disorders
AI 40.0
Base 32.6
Rank 30.7
AI Summary

Proof-of-concept study showing mobile EEG can detect condition-dependent behavioral and event-related potential changes during an inhibitory-control task while walking in Parkinson's disease, with levodopa primarily modulating early sensory-perceptual components and DBS affecting later cognitive…

Why It Matters

Provides a feasible ambulatory neurophysiological biomarker for cognition–gait interactions that can help design and power trials of levodopa/DBS and other interventions, though it offers limited direct therapeutic mechanistic targets.

E
Group Cognitive Stimulation Therapy for people living with Parkinson's disease and dementia.
PMID 42033413 Published: 2026-04-25 Ingested: 2026-04-28 08:58 PM Aging & mental health
AI 25.0
Base 32.6
Rank 30.7
AI Summary

Small within-subject pilot (n=20) found 7 weeks of bi-weekly group Cognitive Stimulation Therapy improved cognition in people with Parkinson's disease dementia, with increased caregiver assistance and high satisfaction.

Why It Matters

Relevant as a non‑pharmacologic, symptomatic approach for cognitive symptoms in PDD, but offers limited mechanistic insight, biomarker data, or direct value for Parkinson's drug discovery due to small sample and preliminary design.

E
[The effectiveness of citicoline in the treatment of cognitive disorders].
PMID 41984564 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
AI 45.0
Base 30.6
Rank 30.5
AI Summary

This review/meta-analysis reports that citicoline improves cognitive impairment across vascular and neurodegenerative conditions and cites evidence for benefit in mild cognitive impairment in Parkinson's disease with suggested dosing regimens (e.g., 1000 mg/day for 12–18 months).

Why It Matters

The paper highlights a clinically tested, readily repurposable agent with pragmatic dosing data for symptomatic cognitive benefit in PD, offering translational trial potential, but it lacks PD-specific mechanistic or disease‑modifying evidence (alpha‑synuclein, mitochondrial, inflammatory, or…

E
Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease".
PMID 42045162 Published: 2026-04-27 Ingested: 2026-04-28 08:58 PM Journal of medicinal chemistry
AI 20.0
Base 30.2
Rank 30.2
AI Summary

This entry is a correction notice to a report on potent, selective, CNS-penetrant macrocyclic LRRK2 inhibitors for Parkinson's disease and contains no new experimental abstract or actionable data.

Why It Matters

While LRRK2-targeting, CNS-penetrant macrocyclic inhibitors are highly relevant to PD therapeutic development, a correction notice itself adds little translational value—researchers should consult the original article for the substantive data and implications for drug discovery.

E
Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease.
PMID 42003785 Published: 2026-04-20 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 72.0
Base 30.8
Rank 29.2
AI Summary

This study finds elevated monocyte LRRK2 kinase activity (pRab10Thr73) in PD patients carrying the Asian-prevalent p.G2385R variant—markedly higher in rare double p.G2385R/p.R1628P carriers—and reduced pLRRK2Ser935 across PD groups, with a subset of idiopathic PD patients also showing increased…

Why It Matters

Provides actionable blood-based LRRK2 activity biomarkers that support biochemical stratification and target-engagement monitoring to expand and refine LRRK2 inhibitor trials beyond genetically defined carriers.

E
The genetic spectrum of LRRK2 variants in Parkinson's disease: findings from a large Chinese cohort.
PMID 41904258 Published: 2026-03-28 Ingested: 2026-04-28 08:58 PM NPJ Parkinson's disease
AI 70.0
Base 30.8
Rank 29.2
AI Summary

Sequencing of LRRK2 in 20,519 Chinese individuals reveals enrichment of known pathogenic/likely pathogenic variants in PD, identifies novel candidate pathogenic variants (e.g., p.A312V, p.M968K, p.R1320S), and confirms common PD-associated alleles (p.A419V, p.R1628P, p.G2385R) with no similar…

Why It Matters

This large-population genetic map of LRRK2 enables patient stratification and clinical-trial enrichment for LRRK2-targeted therapies, prioritizes novel variants for functional follow-up, and supports development of genotype-guided biomarkers and personalized PD interventions.

E
Neuromodulation-induced normalization of cortical metastable dynamics signatures in Parkinson's disease.
PMID 42009672 Published: 2026-04-20 Ingested: 2026-04-28 08:58 PM NPJ Parkinson's disease
AI 68.0
Base 30.8
Rank 29.2
AI Summary

Using resting-state fMRI and a novel Weighted Eigenvector Dynamics Analysis, the study shows that STN-DBS and noninvasive STN-targeted temporal interference stimulation normalize cortical metastable dynamics by restoring occupancy of a metastable substate (a VN–SMN/VAN decoupling) that correlates…

Why It Matters

Provides a translatable, network-level biomarker and mechanistic target for optimizing invasive and noninvasive neuromodulation in PD, potentially improving patient selection and stimulation strategies for motor symptom relief.

E
Soft Neural Interfaces for Circuit-Level Analysis of Magnetogenetic Deep Brain Stimulation in Parkinson's Disease Models.
PMID 41983317 Published: 2026-04-15 Ingested: 2026-04-28 08:58 PM Advanced healthcare materials
AI 68.0
Base 30.8
Rank 29.2
AI Summary

This paper presents a biointegrable soft neural interface enabling stable multi-regional recordings in Parkinson's disease mice and shows that wireless magnetogenetic DBS selectively modulates pathological beta-band oscillations and cortico‑basal ganglia‑thalamic synchrony, with therapeutic effects…

Why It Matters

By combining a minimally damaging recording platform with mechanistic electrophysiology, the study identifies durable circuit-level modulation and candidate biomarkers (beta oscillations, inter-regional synchrony) that could guide development and optimization of novel, potentially translatable…

E
Profiling the Structural Heterogeneity of Monomeric α-Synuclein From the Single-Molecule Level Using MspA Nanopores.
PMID 41978376 Published: 2026-04-13 Ingested: 2026-04-28 08:58 PM Angewandte Chemie (International ed. in English)
AI 68.0
Base 30.8
Rank 29.2
AI Summary

The authors develop an MspA nanopore single-molecule assay that resolves three reproducible current states of monomeric α‑synuclein, maps them to α‑helical and random‑coil subdomains, and generates a biophysical parameter matrix to profile structural heterogeneity of variants.

Why It Matters

By directly sensing monomeric α‑synuclein conformations at single‑molecule resolution, this method can reveal early misfolding mechanisms, enable screening for compounds that stabilize nonpathogenic conformers, and serve as a potential biomarker platform for Parkinson's therapeutic discovery.

E
AI 68.0
Base 30.8
Rank 29.2
AI Summary

31P MR spectroscopy detected altered midbrain energy metabolism (lower Pi/PCr, higher ATP/Pi) in early-stage PD versus mimics, correlated with nonmotor/autonomic symptoms, and achieved high diagnostic accuracy (AUC 0.90) outperforming iron and neuromelanin MRI.

Why It Matters

This provides a noninvasive, quantitative biomarker of mitochondrial/energy dysfunction with strong translational value for early differential diagnosis, patient stratification, and as a potential target-engagement or efficacy readout for metabolism-focused PD therapies.

E
Effects of neuromelanin buildup in rodent nigral dopamine neurons: implications for sex-biased vulnerability in Parkinson's disease.
PMID 41933664 Published: 2026-06-01 Ingested: 2026-04-28 08:58 PM Neurobiology of disease
AI 65.0
Base 30.8
Rank 29.2
AI Summary

Using a viral hTyr rat model to induce neuromelanin, the study shows that NM accumulation alters nigral dopamine neuron survival, intrinsic firing and mitochondrial function with higher NM levels in males and sex-biased motor and non-motor (anxiety) phenotypes.

Why It Matters

By linking neuromelanin buildup to mitochondrial dysfunction and sex-specific vulnerability in a manipulable preclinical model, the work offers a mechanistic target and platform for developing sex-tailored neuroprotective strategies and biomarkers for Parkinson's disease.

E
Automating Subthalamic Deep Brain Stimulation Programming with Evoked Resonant Neural Activity in Parkinson's Disease.
PMID 41986243 Published: 2026-04-15 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 65.0
Base 30.8
Rank 29.2
AI Summary

This study demonstrates that an automated programming algorithm using intraoperatively recorded evoked resonant neural activity (ERNA) produces acute motor improvements equivalent to expert clinician and imaging-guided STN-DBS settings in Parkinson's patients, with ERNA recordings taking under one…

Why It Matters

Offers a rapid, objective biomarker-driven approach to standardize and scale DBS programming—improving consistency, enabling workflow efficiency and potential closed-loop neuromodulation—representing high translational clinical value though not a novel molecular therapeutic target.

E
Pathological cortico-STN beta coupling in Parkinson's disease is confined to beta bursts.
PMID 42039421 Published: 2026-04-13 Ingested: 2026-04-28 08:58 PM bioRxiv : the preprint server for biology
AI 65.0
Base 30.8
Rank 29.2
AI Summary

Using intraoperative STN local field potentials and simultaneous cortical ECoG from seven PD patients, the study shows cortico‑STN beta-band coupling is significantly elevated during brief high‑amplitude beta bursts and collapses to surrogate levels outside those bursts.

Why It Matters

This provides an actionable, time‑resolved biomarker (beta bursts) that supports burst‑targeted adaptive deep brain stimulation strategies and improved closed‑loop neuromodulation for Parkinsonian motor symptoms.

E
Remote Magnetomechanical Neuromodulation Uncovers Therapeutic Mechanisms for Alleviating Parkinsonian Symptoms in Freely Moving Mice.
PMID 41933910 Published: 2026-04-03 Ingested: 2026-04-28 08:58 PM Advanced science (Weinheim, Baden-Wurttemberg, Germany)
AI 65.0
Base 30.8
Rank 29.2
AI Summary

The paper presents a wireless, minimally invasive magnetomechanical deep brain stimulation using magnetite nanodiscs to remotely modulate subthalamic nucleus activity and restore motor function in hemiparkinsonian mice.

Why It Matters

It offers a potentially translatable, electrode-free DBS alternative that can reversibly control Parkinsonian motor symptoms without implants or genetic modification, providing a novel therapeutic delivery strategy despite remaining questions about safety, delivery, and long-term efficacy.

E
TuneS: Patient-specific model-based optimization of contact configuration in deep brain stimulation.
PMID 42024925 Published: 2026-04-23 Ingested: 2026-04-28 08:58 PM IEEE transactions on bio-medical engineering
AI 62.0
Base 30.8
Rank 29.2
AI Summary

This study presents TuneS, a patient-specific, model-based pipeline to optimize deep brain stimulation contact configurations and targets (including STN motor subdivisions and streamlines) to maximize intended target engagement while minimizing stimulation of avoidance regions.

Why It Matters

By providing a systematic, constraint-aware way to predict and evaluate DBS settings for individual PD patients, TuneS can improve clinical outcomes, reduce side effects, and accelerate optimization in both routine care and clinical trials, though it does not address underlying disease-modifying…

E
Alpha synuclein variants significantly influence the propensity for clustering and pore formation in giant unilamellar vesicles.
PMID 41990982 Published: 2026-04-14 Ingested: 2026-04-28 08:58 PM Biochimica et biophysica acta. Biomembranes
AI 62.0
Base 30.8
Rank 29.2
AI Summary

Using DOPC-cholesterol giant unilamellar vesicles, the paper demonstrates that the N-terminal region of α‑synuclein is required for membrane binding and vesicle clustering, while full-length and C‑terminal truncated forms promote clustering and membrane permeabilization, with monomers causing…

Why It Matters

By pinpointing the N-terminus as essential for membrane interaction and showing variant-dependent pore formation, the work provides a mechanistic handle that could guide strategies to block α‑synuclein–membrane binding and reduce membrane permeabilization implicated in Parkinson’s disease pathology.

E
Consistency of Serial CSF alpha-Synuclein Seed Amplification Assay Results in the Parkinson's Progression Marker Initiative.
PMID 41959813 Published: 2026-04-03 Ingested: 2026-04-28 08:58 PM medRxiv : the preprint server for health sciences
AI 62.0
Base 30.8
Rank 29.2
AI Summary

Longitudinal analysis of 1,238 PPMI participants shows CSF alpha-synuclein seed amplification assay results are highly stable over a median 2-year follow-up (~90%+ concordance across PD, prodromal, and control groups) with low rates of conversion between positive and negative.

Why It Matters

Confirms aSyn-SAA is a reliable, durable biomarker suitable for patient selection, stratification, and longitudinal outcome or engagement measures in PD therapeutic trials and prodromal detection efforts.

E
A Randomized, Double-Blinded, Placebo-Controlled QTc Study to Evaluate BIA 28-6156 Effect on Cardiac Repolarization in Healthy Volunteers.
PMID 41957689 Published: 2026-04-01 Ingested: 2026-04-28 08:58 PM Clinical pharmacology in drug development
AI 62.0
Base 30.8
Rank 29.2
AI Summary

Phase 1 randomized crossover thorough QTc study in 37 healthy volunteers found BIA 28-6156, an allosteric GCase activator for GBA-associated Parkinson’s, produced no clinically relevant QTc prolongation and was generally well tolerated.

Why It Matters

By demonstrating cardiac safety and tolerability of a GBA-targeted small molecule, this de-risks further clinical development of a potentially disease-modifying therapy for GBA-associated PD and supports progression to efficacy trials.

E
Enhancing Parkinson's Disease Staging: An Integrative Deep Learning Framework for Multimodal Feature Selection.
PMID 41910849 Published: 2026-03-30 Ingested: 2026-04-28 08:58 PM Journal of molecular neuroscience : MN
AI 62.0
Base 30.8
Rank 29.2
AI Summary

MAFNet is an end-to-end deep‑learning pipeline that integrates temporal denoising, swarm-based feature selection, and graph‑attention multimodal fusion to stage Parkinson's disease from SNPs, neuroimaging, and UPDRS data, reporting 97.6% accuracy on PPMI (n=200) and nominating LRRK2 variants,…

Why It Matters

The method has strong translational potential for biomarker-driven patient stratification and real‑time clinical staging to support precision trials and therapeutic decision‑making, but its high reported performance and biomarker claims need replication in larger, independent cohorts before…

E
AI 60.0
Base 30.8
Rank 29.2
AI Summary

This cross-cohort study found targeted plasma proteomics markedly outperformed whole-blood transcriptomics and multimodal fusion for classifying Parkinson's disease (best proteomic Random Forest AUROC=0.872) and derived a Proteomic Severity Index that explained ~28% of motor severity variance with…

Why It Matters

By demonstrating robust, externally validated blood-based proteomic biomarkers for PD and a severity index, the work provides a practical, translatable tool for diagnosis, patient stratification, and trial endpoint development—even though it does not directly identify new therapeutic targets.

E
Authentic Phosphorylation of α-Synuclein at Ser129 Reveals Functional Differences Not Captured by the S129D Phosphomimetic.
PMID 42024867 Published: 2026-04-23 Ingested: 2026-04-28 08:58 PM ACS chemical biology
AI 60.0
Base 30.8
Rank 29.2
AI Summary

The paper presents a robust bacterial coexpression method to produce authentic Ser129-phosphorylated α-synuclein and demonstrates that true pS129 differs from the S129D phosphomimetic in local structure, aggregation behavior, and modest neuronal toxicity.

Why It Matters

By providing a scalable source of chemically authentic pS129, the work corrects potential artifacts from phosphomimetics, enabling more accurate mechanistic studies and drug screening efforts (including kinase-targeting strategies) relevant to Parkinson's disease therapeutics.

E
AI 60.0
Base 30.8
Rank 29.2
AI Summary

Whole-exome sequencing, burden testing, Mendelian randomization, and colocalization in a European cohort identified enrichment of rare variants in multiple DNAJC genes and provide convergent genetic evidence implicating DNAJC13 (and shared signals for DNAJC19) as Parkinson's disease susceptibility…

Why It Matters

By genetically linking DNAJC family members—chaperone/co‑chaperone proteins involved in protein homeostasis and endosomal/vesicular trafficking—to PD, the study highlights mechanistic pathways (protein folding, endosome‑lysosome dysfunction) that are relevant and potentially targetable for drug…

Previous
Page 24 of 61
Next
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic
Full Neurocompute Infographic